Clinical Assessment & Management Plan

Step 1: Interpret the Current Data

Working Diagnosis

Anemia of CKD (AoC/AoI) + concurrent absolute iron deficiency — the dominant mechanism is EPO deficiency from CKD (eGFR ~37), compounded by iron deficiency (TSAT 12.7%, low serum iron, borderline-low ferritin).

Step 2: What Is Still Missing / What to Do Next

A. Confirm Iron Status More Precisely

• Reticulocyte Hemoglobin Content (CHr / Ret-Hb) — the most sensitive early marker of functional iron deficiency for erythropoiesis; a CHr <29 pg strongly supports iron-deficient erythropoiesis. Request if your lab supports it.
• Serum transferrin — optional; already inferred from TIBC.
• Folate level — not yet done. Get it (MCV is normal so less likely, but still worth checking in a 75-year-old on multiple medications).
• Peripheral blood smear — look for pencil cells, hypochromic cells, any dysplastic changes to rule out MDS (myelodysplastic syndrome), which is a common cause of refractory normocytic anemia in elderly females.

B. Rule Out Myelodysplastic Syndrome (MDS)

• Peripheral smear — look for dysgranulopoiesis, hypersegmented neutrophils, macroovalocytes, or pseudo-Pelger-Huët cells.
• If smear is suggestive or anemia doesn't respond to iron/EPO → refer to hematology for bone marrow biopsy.

C. Assess CKD Stage Properly

• Current creatinine 1.35 in a 75F → eGFR ~37 by CKD-EPI. This is CKD Stage 3b if chronic (>3 months) — anemia of CKD is expected and common at this level.
• Confirm chronicity: is the elevated creatinine new (AKI) or longstanding? Check previous records. If AKI resolving → repeat RFT in 2–4 weeks.
• 24-hr urine protein / spot urine ACR — if not done yet, to assess degree of proteinuric CKD.
• Renal USG with doppler — already done (no hepatosplenomegaly); confirm bilateral small kidneys to support chronicity.

D. PTH and Bone Profile

• iPTH (intact PTH)
• Serum calcium, phosphate
• Vitamin D3 is 22.5 (insufficient) — already identified; treat.

E. Thyroid Function

• Hypothyroidism in a 75F with CKD + DM + HTN is common and causes normocytic anemia. TSH if not done.

Step 3: Treatment Plan

1. Iron Replacement (First Priority)

Per KDIGO 2012 and NKF Primer on Kidney Diseases (8e): In CKD patients not on dialysis, IV iron is preferred when TSAT <20% and ferritin <100 ng/mL, or when oral iron is not tolerated.

• Oral iron (ferrous sulfate 200 mg TDS or ferrous ascorbate) — first trial for 3 months if tolerated. However, oral absorption is impaired in CKD due to elevated hepcidin.
• IV iron (ferric carboxymaltose or iron sucrose) — preferred if oral fails or poor absorption suspected. Ferric carboxymaltose 500–1000 mg IV as single infusion after ensuring no active infection.
• Recheck iron studies + CBC after 4–6 weeks of treatment.

2. Erythropoiesis-Stimulating Agent (ESA)

ESA should not be initiated until Hb <10 g/dL in NDD-CKD patients AND other correctable causes (especially iron deficiency) have been addressed first.

• This patient's Hb is 8.1 g/dL — she qualifies for ESA initiation once iron stores are being repleted.
• Correct iron deficiency first (at least give IV iron), then start ESA if Hb remains <10.
• Agent: Erythropoietin alpha (EPO-α) 50 units/kg SC weekly or three times weekly; or darbepoetin alpha 0.45 µg/kg every 2 weeks.
• Target Hb: 10–11.5 g/dL (do NOT target >13 g/dL — the CHOIR and TREAT trials showed increased cardiovascular events and stroke with higher targets).
• Monitor Hb monthly during dose titration.

3. Vitamin D Supplementation

• Cholecalciferol (D3) 60,000 IU once weekly × 8 weeks, then maintenance 1000–2000 IU/day.
• Vitamin D deficiency worsens EPO resistance and secondary hyperparathyroidism.

4. CKD-Specific Management

• RAAS blockade (ACE inhibitor or ARB) — already likely given HTN + DM + CKD; ensure dose-adjusted. However, note ACE inhibitors can blunt EPO response.
• Tight glycemic control (HbA1c target ~7–8% in elderly with CKD to avoid hypoglycemia).
• Tight BP control (<130/80 per guidelines in CKD + DM).
• Dietary phosphate restriction if phosphate elevated; avoid nephrotoxins.
• Nephrology referral — GFR ~37, anemia requiring ESA, AKI on CKD → formal nephrology co-management is appropriate.

5. Do NOT Do Yet

• GI endoscopy — not indicated at this stage: stool OB ×2 negative, no symptoms of GI bleeding, and the clinical picture fits CKD anemia well. Defer unless anemia worsens, stool OB becomes positive, or iron deficiency doesn't respond to replacement.
• Blood transfusion — avoid unless Hb falls rapidly below 7 or patient is symptomatic (angina, dyspnea at rest). Allosensitization risk and fluid overload in CKD.

Step 4: Follow-Up Timeline

Summary

1. Replete iron (IV iron preferred in CKD)
2. Start ESA once iron is partially corrected (Hb <10)
3. Target Hb 10–11.5 g/dL — do not over-correct
4. Correct vitamin D insufficiency
5. Check PTH, folate, TSH, peripheral smear to complete workup
6. Nephrology co-management for CKD + anemia requiring ESA